Acacia Honey Modulates Cell Cycle Progression, Pro-inflammatory Cytokines and Calcium Ions Secretion in PC-3 Cell LinesMuhammad Aliyu1,2,3*, Oyeronke A Odunola1, Ahsana D Farooq2, Ahmed M Mesaik3, Muhammad I Choudhary2,3, Beenish Fatima3, Tariq A Qureshi3 and Ochuko L Erukainure2
- *Corresponding Author:
- Muhammad Aliyu
Department of Biochemistry
University of Ibadan, Ibadan
Oyo State, Nigeria
E-mail: [email protected]
Received date: October 18, 2012; Accepted date: November 08, 2012; Published date: November 10, 2012
Citation:Aliyu M, Odunola OA, Farooq AD , Mesaik AM , Choudhary MI, et al. (2012) Acacia Honey Modulates Cell Cycle Progression, Pro-inflammatory Cytokines and Calcium Ions Secretion in PC-3 Cell Line. J Cancer Sci Ther 4: 401-407. doi: 10.4172/1948-5956.1000174
Copyright: © 2012 Aliyu M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Purpose: Both anti-CD20 antibodies (ibritumomab; ZEVALIN® and tositumomab; BEXXAR®) currently used for radioimmunotherapy of B cell non-Hodgkin’s lymphoma are murine immunoglobulins. The aim of this feasibility study was to evaluate the safety and efficacy of radioimmunotherapy with a human chimeric anti-CD20 antibody labelled with Yttrium-90 (90Y-rituximab) in patients with B cell lymphoma.
Methods: Patients with CD20+ B-cell lymphoma in partial remission or with progressive disease after at least one line of therapy were included. 90Y-rituximab was administered according to a similar schedule as currently approved by the European Medicines Agency for the treatment with 90Y-ibritumomab tiuxetan (ZEVALIN®): a first infusion of rituximab 250 mg/m² is repeated one week later and directly followed by the injection of 90Y-rituximab (14,8 MBq/kg). 18FDG-PET/CT was performed before treatment and repeated 3 months after for response assessment.
Results: Twenty-six patients were treated with 90Y-rituximab. Disease histologies included mainly follicular lymphomas (53%). Toxicity was primarily haematological. The incidence of grade 3-4 neutropenia, thrombocytopenia and anemia were 34%, 38%, and 8% respectively, with spontaneous recovery in all but one patient that needed autologous stem cell transplant for refractory thrombocytopenia. Among the relevant long-term side effects, one patient developed secondary myelodysplasia 2 years after the treatment. The overall response rate was 88% (95% CI: 70%-98%), including 65% complete metabolic responses and 23% partial metabolic responses. After a median follow-up of 29.6 months, the Kaplan-Meier estimated median progression-free survival was 9, 1 months (95% CI 6,1-17,9). Median time to next treatment was 24 months (95% CI: 12, 2-28).
Conclusion: Radioimmunotherapy with 90Y-rituximab in patients with relapsed CD20+ B-cell lymphomas is safe, well tolerated and effective when the ZEVALIN® treatment schedule is used.